Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BURAN benralizumab airway dynamics study in severe eosinophilic asthma
2022-000152-11Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of benralizumab in eosinophilic asthma (EA) and asthma, sponsored by AstraZeneca. Primary endpoint: Change in total mucus volume at TLC. Started Jul 2022; status: completed.
02
Drugs
benralizumab
03
Conditions
eosinophilic asthma (EA)asthma
Beyond the preview
Go deeper on 2022-000152-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000152-11.